Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cardio Diagnostics has developed and validated AI-powered blood-based diagnostic tests—PrecisionCHD™ and Epi+Gen CHD™—for the detection, management, and three-year event risk prediction of coronary heart disease. Clinical validation studies demonstrated that PrecisionCHD achieved sensitivity up to 82% and specificity up to 82% in independent cohorts. The company’s solutions are being adopted by a growing number of provider organizations across the US.[4][7][9]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cardio Diagnostics.